Last checked at 
(Sharecast News) - AstraZeneca said its Imfinzi bladder cancer treatment did not meet primary endpoints in the phase three DANUBE trial against standard-of-care (SoC) chemotherapy for patients with an advanced stage of the disease.
Imfinzi is being developed in patients with unresectable, locally advanced or metastatic bladder cancer in the Phase III NILE trial either in combination with chemotherapy or with chemotherapy and tremelimumab, Astra said.
The drug is also being tested in earlier stages of bladder cancer in the phase III NIAGARA trial in combination with chemotherapy, and in the phase III POTOMAC trial in combination with SoC Bacillus Calmette-Guerin immunotherapy.
Astra's executive vice-president for oncology Jos? Baselga said the company remained committed to "addressing unmet needs in bladder cancer and the potential for immunotherapy to improve outcomes for these patients".
"The results from this trial will inform our comprehensive phase III development programme in bladder cancer. We look forward to the results of the phase III NILE trial also in the 1st-line metastatic setting, and we continue to advance clinical trials for patients at earlier stages of the disease," Baselga said.
In 2018, about 550,000 people were diagnosed with bladder cancer around the world and 200,000 died from the disease, Astra said.
Imfinzi is approved for patients with locally advanced or metastatic bladder cancer previously treated with platinum-containing chemotherapy in 15 countries, including the US.
It is also being tested as a monotherapy and in combinations including with tremelimumab, an anti-CTLA4 monoclonal antibody and potential new medicine, as a treatment for patients with bladder cancer, head and neck cancer, liver cancer, biliary tract cancer, cervical cancer and other solid tumours.
15 Feb 2024 14:44
UK dividends calendar - next 7 days
| Friday 16 February | |
| JPMorgan Asia Growth & Income PLC | dividend payment date |
| JPMorgan Japan Small Cap Growth & Income PLC | dividend payment date |
| Murray International Trust PLC | dividend payment date |
| Premier Miton Group PLC | dividend payment date |
| Schroder Oriental Income Fund | dividend payment date |
| Solid State PLC | dividend payment date |
| Monday 19 February | |
| no events scheduled | |
| Tuesday 20 February | |
| Invesco Bond Income Plus Ltd | |
| Wednesday 21 February | |
| no events scheduled | |
| Thursday 22 February | |
| abrdn Asia Focus PLC | ex-dividend payment date |
| Alumasc Group PLC | ex-dividend payment date |
| AstraZeneca PLC | ex-dividend payment date |
| BlackRock Throgmorton Trust PLC | ex-dividend payment date |
| Braemar PLC | ex-dividend payment date |
| easyJet PLC | ex-dividend payment date |
| Ecofin US Renewables Infrastructure Trust PLC | ex-dividend payment date |
| Endeavour Mining PLC | ex-dividend payment date |
| FRP Advisory Group PLC | ex-dividend payment date |
| Gateley Holdings PLC | ex-dividend payment date |
| GSK PLC | ex-dividend payment date |
| Hercules Site Services PLC | ex-dividend payment date |
| Jersey Electricity PLC | ex-dividend payment date |
| Land Securities Group PLC | ex-dividend payment date |
| Molten Ventures VCT PLC | ex-dividend payment date |
| Northern Bear PLC | ex-dividend payment date |
| Redrow PLC | ex-dividend payment date |
| Samuel Heath & Sons PLC | ex-dividend payment date |
| Titon Holdings PLC | ex-dividend payment date |
| Unilever PLC | ex-dividend payment date |
| Van Elle Holdings PLC | ex-dividend payment date |
| Virgin Money UK PLC | ex-dividend payment date |
| Witan Investment Trust PLC | ex-dividend payment date |
| Comments and questions to newsroom@alliancenews.com | |
| A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
| Copyright 2024 Alliance News Ltd. All Rights Reserved. | |